Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 229

Posts Tagged ‘treatments’

Psoriasis Treatments

Posted by fidest press agency su venerdì, 22 giugno 2018

A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis (PsO) every year in the United States, affecting 2.2% of the population. Approximately 80% of those affected have mild-to-moderate psoriasis, while 20% have moderate-to-severe psoriasis, which is often treated with immunology drugs. These drugs command a high price, but there may be hope for better options in the future.People with psoriasis suffer from the overproduction of skin cells, which causes the redness and inflammation typically found on elbows, knees, or the scalp. The disease is usually associated with other serious health conditions, often involving the immune system. Crohn’s disease and ulcerative colitis are some examples, both of which can be up to 7 times more prevalent in psoriasis patients.Psoriasis patients have a number of treatment options, ranging from non-steroidal anti-inflammatory drugs for initial treatment to biologics, which are more often used in moderate-to-severe forms of the disease. The PsO market is dominated by drugs such as Humira®, Enbrel®, Remicade® and Stelara®, but more competition is coming soon from biosimilars as patents begin to expire.Research by iData shows that the average annual drug cost per patient in the U.S. is over $60,000. Stelara® and Humira® are the most-prescribed immunology drugs for psoriasis treatment, due to their high efficacy, and are clearly benefiting from the lack of competition, which enables them to sell at these prices.The U.S. psoriasis market is valued at almost $5 billion, growing year over year. According to this latest study, the PsO market is expected to reach $6.33 billion by 2023. This market growth is driven by the high cost of the biologics, unmet needs in the psoriasis space, and the efficacy of anti-TNF biologics. “Despite this trend, biologics are seeing a lower growth rate as a direct result of competition from the immunology biosimilar market, which will experience a compound annual growth rate exceeding 30% over the forecast period,” says Dr. Kamran Zamanian, President and CEO of iData Research.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , | Leave a Comment »

WHO issuing updated guidelines for treatment of hepatitis C infection

Posted by fidest press agency su martedì, 26 aprile 2016

Hepatitis program1Hepatitis programBarcelona, Spain, In view of the continued rapid progress in the development of new treatments for hepatitis C infection, the World Health Organization (WHO) is issuing updated treatment guidelines. The guidelines promote the transition to newer, more effective medicines that have the potential to cure most persons living with hepatitis C infection. WHO issued its first-ever recommendations on the treatment of hepatitis C virus (HCV) in 2014. Since then, several new medicines have been introduced and marketed. These medicines, called direct-acting antivirals (DAAs), are more effective and easier to use than established treatment regimens. Furthermore, they have been included in WHO’s Model List of Essential Medicines. Treatment with DAAs is short in duration (8–12 weeks), easy to take (as few as 1 pill per day), has few side effects, and results in a cure for more than 90% of people treated. This is a vast improvement from older treatments, which cured less than half of the people treated, required weekly interferon injections for up to 12 months, and often resulted in severe, sometimes fatal, side effects.The new guidelines also provide guidance on which specific regimens should be used (called “preferred regimens”) based on a patient’s clinical history as well as the genotype of HCV (there are 6 genotypes). These preferred regimens simplify treatment decisions by recommending only 3 treatment epatite programregimens for patients without cirrhosis and an additional 2 for patients with cirrhosis.The updated guidelines are intended to promote the scale-up of HCV treatment, particularly in low- and middle-income countries where few people currently have access to hepatitis treatment, despite also being where most people with HCV live. WHO recognizes that implementation of the recommendations may not be immediate, because the treatments can be expensive and the medicines are not yet approved in many countries.The price of DAAs varies dramatically. The cost to treat a single patient in some high-income countries can exceed US$100 000. However, following the introduction of generic versions of DAAs, the price in other countries, such as India, is less than US$ 500 to treat a single patient.Approximately 130–150 million people are estimated to be infected with HCV. Each year, an estimated 700 000 people die from HCV-related complications including fatty liver (cirrhosis), cancer (hepatocellular carcinoma) and liver failure. Unfortunately, many people with HCV only learn about their infection when they develop symptoms from cirrhosis or liver cancer. Because the prices are rapidly dropping, and because the medicines are easy to use, they have the potential to dramatically reduce the number of deaths due to hepatitis C infection. (fonte: World Health Organization – Who http://www.who.int/hepatitis/news-events/hepatitis-c-guidelines-2016-story/en/)

Posted in Cronaca/News, Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

“MS: Future treatments and new goals”

Posted by fidest press agency su venerdì, 12 novembre 2010

Vienna, 12 -13 Novembre 2010 Serono Symposia International Foundation riunirà alcuni tra i massimi esperti internazionali nel campo della Sclerosi Multipla per discutere gli sviluppi futuri nel trattamento di questa patologia che offrirà ai pazienti una migliore qualità di vita. L’obiettivo dell’incontro è quello di fornire ai partecipanti un aggiornamento sui target farmacologici, sull’efficacia e sulla sicurezza della nuova generazione di terapie orali nella Sclerosi Multipla, oltre che di evidenziare ciò che può essere realisticamente ottenuto grazie all’impiego di questi nuovi trattamenti. L’incontro è suddiviso in quattro sessioni. Nel corso delle prime tre sessioni si discuterà del ruolo delle cellule immunitarie nella Sclerosi Multipla e della sfida che attende i medici legata alle terapie orali sperimentali che potrebbero venire introdotte nei prossimi anni. Queste nuove terapie non sostituiranno quelle attualmente disponibili, e che fino ad oggi hanno rappresentato un’arma insostituibile conto la Sclerosi Multipla, ma saranno combinate con esse in complessi protocolli terapeutici  che offriranno opzioni innovative per trattamenti personalizzati sulla base delle caratteristiche sia del paziente sia della patologia. Alla luce di ciò, la quarta ed ultima sessione del simposio prevede un gruppo di discussione che aprirà un dibattito su come potrà cambiare, di pari passo nel corso dei prossimi anni, la gestione dei pazienti. Il nostro obiettivo – ha concluso Professor Giancarlo Comi – è la personalizzazione del trattamento e questo richiede un uso intelligente di tutti i dati prognostici e un’approfondita conoscenza del profilo di rischio-beneficio di ogni terapia. Questo evento si propone, pertanto, di accrescere le conoscenze in questo ambito al fine di fornire al paziente la migliore terapia possibile”.
Serono Symposia International Foundation è un’organizzazione no profit con sede a Ginevra (Svizzera), che da circa 40 anni, promuove eventi di altissimo livello scientifico nelle aree della Neurologia, Medicina della Riproduzione, Oncologia, Endocrinologia, Dermatologia, Immunologia e Genetica. La missione di Serono Symposia International Foundation è quella di fornire Educazione Continua in Medicina rivolta a medici, ricercatori, infermieri, farmacisti e ad altri professionisti della sanità, attraverso strumenti sempre più aggiornati ed efficaci per migliorare la qualità dell’approccio verso il paziente ed aumentare gli esiti favorevoli delle cure a cui è sottoposto. Serono Symposia International Foundation può oggi vantare l’organizzazione di oltre 1500 congressi scientifici internazionali, la realizzazione di più di 500 pubblicazioni con le più importanti case editrici scientifiche a livello mondiale e di oltre 35  corsi online.

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »